tacrolimus + sirolimus + corticosteroids

This drug is a **combination immunosuppressive regimen** composed of tacrolimus, sirolimus, and corticosteroids. It is utilized primarily to prevent or treat transplant rejection and graft-versus-host disease (GVHD), particularly in settings like kidney transplantation and hematopoietic stem cell transplantation. - **Tacrolimus** is a calcineurin inhibitor that suppresses T-cell activation by inhibiting interleukin-2 (IL-2) production. - **Sirolimus** (rapamycin) inhibits mTOR (mechanistic target of rapamycin), blocking IL-2 driven T-cell and B-cell proliferation independently of calcineurin. - **Corticosteroids** broadly modulate inflammation and immune responses via genomic and non-genomic mechanisms, including suppression of multiple cytokines and leukocyte migration. Together, this combination provides **synergistic immunosuppression** acting at different points in the immune activation cascade, reducing the risk of acute and chronic rejection but with increased risk of adverse effects including renal dysfunction, myelosuppression, infection, hyperlipidemia, and metabolic complications[2][5][6][7]. This regimen is commonly used in patients with steroid-resistant chronic GVHD, kidney and stem cell transplantation, and other situations requiring intense immunosuppression[2][5][6].

Brand names

Prograf + Rapamune + corticosteroids

Other names

FK506 + rapamycin + glucocorticosteroids